Primary endpoint | |
 Symptomatic NAS | |
Secondary endpoint | |
 1. Incidence of (a)symptomatic NAS | |
 2. Severity of NAS | |
 3. Graft and recipient survival | |
 4. Primary non-function | |
 5. Initial poor function | |
 6. Serum biochemical graft function and injury | |
 7. Hemodynamic status during reperfusion | |
 8. ICU and hospital stay | |
 9. Postoperative complications | |
 10. Renal function | |
  DHOPE group only: | |
 11. Perfusion characteristics | |
 12. Perfusate biochemical graft function and injury | |
 13. Perfusate micro ribonucleic acid (miRNA) | |
 14. Pathobiology of liver and bile duct parenchyma | |
 15. Metabolic function, including new onset diabetes after transplantation (NODAT) | |
 16. Costs | |
 17. Health related quality of life |